Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Raymond Kelleher
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
iNeuro Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Kelleher is a co-founder of and owns equity in iNeuro Therapeutics, a company pursuing drug screening and development efforts to identify positive modulators or activators of Presenilin-1. The research project studies the role of role of Presenilin-1 mutations in Alzheimer’s Disease. The results of the research could potentially enhance interest in the types of compounds being screened by the company. The institution determined that, given the magnitude of the financial interest, Dr. Kelleher’s financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Mechanisms of brain phenotypes caused by FAD-linked Presenilin-1 Mutations
Project Narrative Alzheimer's disease (AD) is the most common neurodegenerative disorder, and mutations in the Presenilin genes are the most common cause of inherited or familial AD (FAD). Results from our recent generation and multidisciplinary analysis of novel mouse models point to an important role for loss of Presenilin function in FAD pathogenesis. In this application, we propose to investigate the mechanisms by which Presenilin mutations impair synaptic function, learning and memory, and neuronal survival in the adult brain. Completion of these studies will advance efforts to understand FAD pathogenesis and devise effective therapies.
Filed on March 08, 2018.
Tell us what you know about Raymond Kelleher's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Raymond Kelleher filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Raymond Kelleher | Massachusetts General Hospital | Conflict of Interest | iNeuro Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.